Kalbe Farma Incar Pertumbuhan Penjualan

IDXchannel

PT Kalbe Farma Tbk (KLBF) optimistis meraih pertumbuhan pendapatan dan laba bersih di tahun ini. Pada akhir tahun ini Kalbe Farma mengincar pertumbuhan laba di kisaran 13 hingga 15% dibandingkan dengan tahun 2023, untuk itu Kalbe optimistis target tersebut dapat tercapai.

Transcript

00:00KB Pharma Tbk is optimistic to achieve a clean income and oil growth this year.

00:10At the end of this year, KB Pharma aims for oil growth in the range of 13% to 15% compared to 2023.

00:18For that reason, KB is optimistic that the target can be achieved.

00:22KB Pharma Tbk is optimistic to achieve a clean income and oil growth this year.

00:31That is reflected in the performance of KLBF in the first semester of 2024, which grew double digit.

00:38Until the first semester of 2024, the clean oil of KLBF increased 18.06% annually to 1.81 trillion.

00:47The achievement of the laba was supported by an increase in sales of KLBF 7.57% to 16.33 trillion rupiah in the first semester of 2024.

00:57KLBF will release a report on financial energy for the period ending September 30, 2024.

01:04The company claims financial energy until the end of Q3 2024 as expected.

01:11The company is committed to continue to improve the KLBF laba until the end of 2024.

01:16The report states that macroeconomically, the KLBF business is directly facing consumers such as health and nutrition products,

01:24is under pressure from the market.

01:27Meanwhile, the business originating from prescription drugs and health equipment is very macroeconomically conducive.

01:33In the future, KLBF will continue to promote the sale of prescription drugs and health equipment.

01:38This segment is expected to be a booster for the growth of the KLBF business,

01:42KLBF is also aiming for a cyclotron business or radiopharmaceuticals that can be used to detect cancer.

Category

Transcript

Be the first to comment

Recommended